PofoliaShared via Pofolia

Chemical Society Reviews· 2015Q1· Review

Facts and fictions about polymorphism

Aurora J. Cruz‐Cabeza, Susan M. Reutzel‐Edens, Joel Bernstein

Short summary

Polymorphism is common, with one in three CSD compounds and at least half of intensively screened drug compounds exhibiting it, but molecular flexibility or size does not predict this behavior.

AI-generated from the title and abstract; the full text is not read.

Key points

  • One in three compounds in the Cambridge Structural Database are polymorphic.
  • At least 50% of intensively screened drug compounds exhibit polymorphism.
  • Molecular flexibility or size does not correlate with a compound's tendency to be polymorphic.
  • Chiral molecules are less prone to polymorphism than achiral ones.
  • Energy differences between polymorphs are typically <1 kcal mol(-1), but conformational polymorphs can differ by up to 2.5 kcal mol(-1).

AI-generated from the title and abstract; the full text is not read.

Abstract

We present new facts about polymorphism based on (i) crystallographic data from the Cambridge Structural Database (CSD, a database built over 50 years of community effort), (ii) 229 solid form screens conducted at Hoffmann-La Roche and Eli Lilly and Company over the course of 8+ and 15+ years respectively and (iii) a dataset of 446 polymorphic crystals with energies and properties computed with modern DFT-d methods. We found that molecular flexibility or size has no correlation with the ability of a compound to be polymorphic. Chiral molecules, however, were found to be less prone to polymorphism than their achiral counterparts and compounds able to hydrogen bond exhibit only a slightly higher propensity to polymorphism than those which do not. Whilst the energy difference between polymorphs is usually less than 1 kcal mol(-1), conformational polymorphs are capable of differing by larger values (up to 2.5 kcal mol(-1) in our dataset). As overall statistics, we found that one in three compounds in the CSD are polymorphic whilst at least one in two compounds from the Roche and Lilly set display polymorphism with a higher estimate of up to three in four when compounds are screened intensively. Whilst the statistics provide some guidance of expectations, each compound constitutes a new challenge and prediction and realization of targeted polymorphism still remains a holy grail of materials sciences.

The authors' abstract, as published at the source. Chemical Society Reviews, 2015 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Physical and Theoretical Chemistry

Physical and Theoretical ChemistryChemistry